Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 29, 2026
Cognex (CGNX) Declines -15.5% Over 30 Days: Valuation Pressures Take Center Stage

Cognex (CGNX) Declines -15.5% Over 30 Days: Valuation Pressures Take Center Stage

Key Takeaways

  • Cognex Corporation (CGNX) shares declined approximately 15.5% over the past 30 days, falling from $68.36 on June 29 to $57.80 as of July 29, 2026.
  • The selloff was driven primarily by valuation compression, broad-based profit-taking, and macroeconomic headwinds rather than company-specific operational weakness.
  • Despite the decline, Cognex's underlying business remains fundamentally strong, with Q1 2026 revenue up 24% year-over-year and adjusted EBITDA doubling from the prior-year period.
  • Insider selling totaling approximately $15 million over the trailing 90 days added to negative sentiment, though institutional ownership remains high at over 88%.
  • Upcoming Q2 2026 earnings, scheduled for release on August 5, represent a critical near-term catalyst that could either stabilize the stock or extend the downtrend.

Understanding Cognex's Business and Market Position

Cognex Corporation is the global technology leader in industrial machine vision, designing and manufacturing vision sensors, systems, software, and industrial barcode readers used to automate manufacturing, logistics, and distribution processes. Headquartered in Natick, Massachusetts, the company has served over 30,000 customers across more than 30 countries for over four decades. Its solutions span industries including automotive, consumer electronics, semiconductors, pharmaceuticals, food and beverage, and packaged goods. Cognex has increasingly emphasized AI-powered vision systems, recently launching the In-Sight 6900 (powered by NVIDIA) and In-Sight 3900 (powered by Qualcomm), positioning itself at the intersection of industrial automation and edge AI. Investors closely follow CGNX as a bellwether for factory automation capital spending and as a high-growth technology name with exposure to secular trends in logistics automation, reshoring, and smart manufacturing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Stock Performance: The Last 30 Days and Quarter

Over the last 30 calendar days, CGNX shares fell from $68.36 (closing price on June 29, 2026) to approximately $57.80 as of July 29, representing a decline of roughly 15.5%. The stock touched its 52-week high of $72.88 on June 30 before embarking on a nearly uninterrupted slide that saw it drop below the $58 level by late July. During this period, CGNX broke below both its 30-day and 50-day simple moving averages, signaling a meaningful shift in short-term momentum.

Zooming out to the broader quarter, the stock has shed approximately 12% from late May levels near $65.85. The quarterly performance reflects a tale of two halves: a strong rally through mid-June that pushed shares to all-time highs, followed by a sharp reversal as macro pressures, valuation concerns, and profit-taking overwhelmed the earlier bullish narrative. The stock remains well above its 200-day moving average near $55, suggesting the longer-term uptrend is still intact despite the recent turbulence.

Factors Behind the 30-Day Selloff

The 30-day decline in CGNX shares was not triggered by a single negative corporate event. Instead, a confluence of macro and sentiment-driven factors weighed on the stock. Rising Treasury yields throughout July pressured high-multiple growth names across the technology and industrial sectors, and Cognex — trading at a forward P/E multiple above 70x — was especially vulnerable. The "higher-for-longer" interest rate narrative re-emerged following stronger-than-expected labor market data, prompting investors to reassess how much they were willing to pay for future earnings.

Profit-taking played a substantial role. CGNX had rallied approximately 78% year-to-date by its June peak, buoyed by a strong Q1 2026 earnings beat, the launch of new AI-powered vision systems, and analyst upgrades from firms including JPMorgan, which initiated coverage with an Overweight rating and a $75 price target. With such outsized gains, the stock became susceptible to even modest shifts in sentiment. A series of insider stock sales totaling roughly $15 million over the trailing 90 days added to the perception that the shares may have become overextended.

Technical exhaustion also contributed. On July 7, CGNX plunged 7.25% in a single session on elevated volume as the stock failed to hold key technical levels. Subsequent sessions saw continued deterioration, with the stock breaching psychological support at $60 in late July. Additionally, the approaching Q2 2026 earnings release (scheduled for August 5) introduced an element of pre-earnings uncertainty, as investors opted to reduce exposure ahead of the report rather than risk a negative surprise. From what I see, this setup highlights how sentiment can override solid fundamentals in the short term.

Performance Drivers Over the Quarter

CGNX entered the quarter with strong momentum following its Q1 2026 earnings report on May 6, which delivered adjusted EPS of $0.34 — a 36% beat versus consensus — and revenue of $268.4 million, up 24% year-over-year. The company raised Q2 guidance to $280–$300 million in revenue and $0.40–$0.44 in adjusted EPS, reflecting broad-based demand across logistics, electronics, packaging, and semiconductor end markets. Management also reaffirmed its target of $35–$40 million in annualized net cost reductions by year-end 2026.

The launch of two next-generation embedded AI vision systems — In-Sight 6900 (NVIDIA-powered) and In-Sight 3900 (Qualcomm-powered) — reinforced Cognex's leadership in edge AI for industrial automation and drove analyst price target increases into the $70–$75 range. These positive developments propelled the stock to its 52-week high in late June.

However, the second half of the quarter revealed the market's sensitivity to valuation. Even as the fundamental story remained largely unchanged, the combination of stretched multiples, insider selling, macro tightening fears, and sector rotation out of high-growth industrials overwhelmed the bullish thesis. The stock's beta of approximately 1.49 amplified downside moves relative to the broader market. While Cognex's operational execution has been strong, the quarterly price action underscores that valuation and macro sentiment can dominate short-term performance for high-multiple names, even when the company-specific narrative is positive. I’m watching this closely as earnings approach.

What Investors Should Watch Next for CGNX

The most immediate catalyst for CGNX is its Q2 2026 earnings report, expected after market close on August 5, with the conference call following on August 6. Analysts project adjusted EPS of $0.42 on revenue of approximately $292 million, within management's guided range of $0.40–$0.44 and $280–$300 million. Investors will scrutinize not only the headline numbers but also forward guidance, margin trends, and commentary on end-market demand, particularly in logistics and electronics.

Beyond earnings, macroeconomic developments around interest rates, PMI readings, and industrial capital spending will remain key swing factors. The Federal Reserve's policy trajectory directly influences how the market values CGNX's high-growth, high-multiple profile. On the company-specific side, the ramp-up of the In-Sight 6900 and 3900 product cycles, progress on the $35–$40 million cost-reduction plan, and any updates on the portfolio optimization strategy (including the completed divestiture of the Japan-focused trading business) will be closely watched. Competitive dynamics in the machine vision space — including from companies such as KEYS and TDY — also merit monitoring. While analyst consensus remains a Moderate Buy with an average price target of approximately $72, the stock's recent price action suggests the market is demanding clearer evidence of sustained execution before rewarding the shares with a renewed premium valuation.

Exploring AI Tools for Market Insights

In a market environment where rapid price swings and sector rotations can challenge even experienced investors, AI-driven trading tools are gaining traction among those seeking data-backed decision support. One resource I turn to is Tickeron's Trending AI Robots page, which curates a selection of top-performing AI trading bots from a platform that hosts hundreds of automated strategies trading across thousands of tickers. Only the most relevant and consistently effective bots appear in this curated section, which spans diverse strategies, timeframes, and performance metrics. Each bot operates using distinct algorithms optimized for specific market conditions, allowing users to explore approaches that align with their individual trading preferences and risk tolerance. For those interested in systematic, algorithm-based trading insights, this page offers a practical starting point.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CGNX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


CGNX in upward trend: 10-day moving average crossed above 50-day moving average on August 07, 2026

The 10-day moving average for CGNX crossed bullishly above the 50-day moving average on August 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGNX's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on CGNX as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CGNX just turned positive on August 03, 2026. Looking at past instances where CGNX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGNX advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where CGNX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

CGNX moved below its 50-day moving average on August 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CGNX broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CGNX entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.258) is normal, around the industry mean (4.470). P/E Ratio (58.303) is within average values for comparable stocks, (89.105). CGNX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.155). Dividend Yield (0.005) settles around the average of (0.011) among similar stocks. P/S Ratio (9.416) is also within normal values, averaging (30.509).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.

Industry description

This industry manufactures electronic products used in various critical and sophisticated technologies, including laser-based systems, circuit and continuity testers, electro-optical measuring instruments and high-speed precision weighing and inspection equipment. Some major companies operating in this business are Canon Inc., Keysight Technologies Inc., and Fortive Corp.

Market Cap

The average market capitalization across the Electronic Equipment/Instruments Industry is 9.25B. The market cap for tickers in the group ranges from 27.54K to 122.53B. KYCCF holds the highest valuation in this group at 122.53B. The lowest valued company is CSEC at 27.54K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Equipment/Instruments Industry was -1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 9%. MVIS experienced the highest price growth at 46%, while FCUV experienced the biggest fall at -47%.

Volume

The average weekly volume growth across all stocks in the Electronic Equipment/Instruments Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was -11% and the average quarterly volume growth was -63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 55
Price Growth Rating: 52
SMR Rating: 79
Profit Risk Rating: 78
Seasonality Score: -14 (-100 ... +100)
View a ticker or compare two or three
CGNX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of machine vision computer systems

Industry ElectronicEquipmentInstruments

Profile
Details
Industry
Electronic Production Equipment
Address
One Vision Drive
Phone
+1 508 650-3000
Employees
2745
Web
https://www.cognex.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Cognex (CGNX) Declines -15.5% Over 30 Days: Valuation Pressures Take Center Stage